6640--KARIUS TEST

Where this opportunity stands

Every notice posted under solicitation 36C24827Q0069 in this department, oldest first.

Next steps for this stage

Standard steps for the notice type; not advice about this buyer.

• Answer the notice: this is when the requirement can still be shaped.
• Contact the contracting officer named on the notice.
• Check who won similar work; they are the likely bidders.

Who won similar work

9 award notices on SAM.gov in the last 24 months. Matched by: Same office (248-NETWORK CONTRACT OFFICE 8 (36C248)), same product/service code (PSC) 6640.

Single-winner award sizes (9): middle half $561K to $3.5M, median $1.5M; range $83K to $31.8M.

Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in. Revenue next to a ticker is the company's last annual revenue from its 10-K.

• Oct 5, 2026CEPHEID SUNNYVALE 94089$561K6640--FY27 Cepheid - Base Plus 4 Option Years (VA-27-00000309)No listed company matched (Materiality N/A)
• May 29, 2026INTERPACE DIAGNOSTICS CORPORATION$1.5M6640--FY26| Thyroid Cancer Molecular Test| Orlando VA & San Juan|No listed company matched (Materiality N/A)
• May 4, 2026SEBIA, INC.$3.6M6640--VISN 8 Electrophoresis TestingNo listed company matched (Materiality N/A)
• Apr 16, 2026POLYMEDCO CANCER DIAGNOSTIC PRODUCTS LLC$3.5M6640--VISN 8 Mail FIT KitsNo listed company matched (Materiality N/A)
• Mar 31, 2026Fisher Scientific Company$2.7M6640--Allergy and Autoimmune Disease (TAM and BP)Materiality: <0.01% of $TMO revenue (Low) SEC
• Oct 1, 2025FRANKLIN YOUNG INTERNATIONAL, INCORPORATED$83K6640--JAK2 Molecular ReagentsNo listed company matched (Materiality N/A)
• May 9, 2025POLYMEDCO CANCER DIAGNOSTIC PRODUCTS LLC$666K6640--FY25: Automated Immunochemical Fecal Occult Blood Test (IFOBT)No listed company matched (Materiality N/A)
• Apr 2, 2025CEPHEID SUNNYVALE 94089$282K6640--FY25 Q3 Micro Molecular Testing (VA-25-00029953)No listed company matched (Materiality N/A)
• Jan 21, 2025BIOMERIEUX INC$31.8M6640--FY25: VISN 8 Molecular Pathogen DetectionNo listed company matched (Materiality N/A)

Materiality: one award's value as a share of the winner's revenue over the latest 12 months in its SEC filings (or its last fiscal year, as noted when you point at it). Low under 1%, Medium 1 to 5%, High 5% or more. Many awards are paid over several years, so this overstates a single year's share.

Competitive landscape

For the 7 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.

Policy around it

Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.

Market

For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.